<DOC>
	<DOCNO>NCT00304265</DOCNO>
	<brief_summary>Post-marketing evaluation reaction follow receipt recommend adolescent pertussis vaccine among person prior vaccination acellular v whole-cell pertussis vaccine . To describe characterize adverse event occur vaccination REPEVAX® ( Tdap-IPV : combination diphtheria , tetanus acellular pertussis inactivate poliomyelitis vaccine ) COVAXIS® ( Tdap : combination diphtheria , tetanus acellular pertussis ) vaccine among two group : Group 1 - adolescent 10-14 year age participate study 371-03/01 ( thus receive 5th dose TRIPEDIA® vaccine ) Group 2 - control 10-14 year age vaccinate least three dose whole-cell pertussis vaccine infancy plus least one subsequent dose pertussis vaccine 2nd 7th year life .</brief_summary>
	<brief_title>Post-marketing Evaluation Reactions Following Receipt Recommended Adolescent Pertussis Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Eligible receive REPEVAX® COVAXIS® vaccine , accord German recommendation booster dose acellular pertussis vaccine 917 year age . Signed date informed consent assent form ( applicable ) obtain prior first study intervention . Judged good health basis report medical history historydirected physical examination . Plans remain study area length trial . The participant parent legal guardian read , write , understand document mentally competent give assent consent . If female , know suspect pregnant time enrollment study plan pregnancy participation trial . Either prior participation study 37103/01 ( Group 1 6th Dose Pertussis Vaccine Group ) document history 3 dos tetanus , diphtheria wholecell pertussis vaccine infancy plus least one subsequent dose pertussis vaccine 2nd 7th year life ( Group 2 5th Dose Pertussis Vaccine Group ) . Has access telephone . Oral temperature &lt; 38.0ºC . Pregnancy nurse child Known suspect primary acquire disease immune system ( condition suspect immunologic component autoimmune diseases [ e.g . rheumatoid arthritis inflammatory bowel disease ] exclude unless meet exclusion criterion 3 5 ) . Malignancy , allergy immunotherapy , receive immunosuppressive therapy ( participant take topical inhaled steroid could include study would participants `` short course '' oral steroid , &lt; 7 day , long two course within previous two week prior vaccination ) . Receipt pertussis , diphtheria tetanuscontaining vaccine within past 3 year . Any unstable significant underlie chronic disease , include ( limited ) malignancy , cardiopulmonary disease , renal , endocrinologic , hematologic hepatic dysfunction . Known impairment neurologic function currently active seizure disorder currently require medication seizure . Personal history physiciandiagnosed laboratoryconfirmed pertussis disease within last 2 year . Receipt blood product immunoglobulin within previous 3 month . Known suspect allergy vaccine vaccine component intend use study . Daily use nonsteroidal antiinflammatory drug . Receipt vaccine investigational product within 30 day prior enrollment , plan receive another vaccine within 28 day receive study vaccine . Chemical dependency ( e.g . alcoholism intravenous drug use include nicotine caffeine ) , base investigator judgment . Known suspected acute infectious respiratory illness time vaccination active symptom sign include one following : rhinorrhea , new cough , pharyngitis , respiratory problem ( e.g . wheezing , shortness breath ) . Any condition , opinion investigator , would pose health risk participant interfere evaluation vaccine . History immediate anaphylaxis , encephalopathy within 7 day , seizure within 3 day receive diphtheria , tetanus , pertussis vaccine . Planned participation another interventional clinical trial present trial period ( participation relate study evaluate immune response study 's vaccination permit ) . Thrombocytopenia bleed disorder would pose contraindication intramuscular ( IM ) vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pertussis ,</keyword>
	<keyword>Diphtheria ,</keyword>
	<keyword>Tetanus ,</keyword>
	<keyword>Poliomyelitis</keyword>
</DOC>